Comparing Claritev (CTEV) & Its Competitors

Claritev (NYSE:CTEV – Get Free Report) is one of 93 publicly-traded companies in the “Healthcare Technology” industry, but how does it compare to its peers? We will compare Claritev to related businesses based on the strength of its institutional ownership, valuation, profitability, earnings, analyst recommendations, dividends and risk.

Risk and Volatility

Claritev has a beta of 1.05, suggesting that its share price is 5% more volatile than the S&P 500. Comparatively, Claritev’s peers have a beta of 1.11, suggesting that their average share price is 11% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and price targets for Claritev and its peers, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Claritev 1 2 6 0 2.56
Claritev Competitors 457 1542 2763 90 2.51

Claritev currently has a consensus price target of $44.83, suggesting a potential upside of 144.59%. As a group, “Healthcare Technology” companies have a potential upside of 54.73%. Given Claritev’s stronger consensus rating and higher possible upside, research analysts plainly believe Claritev is more favorable than its peers.

Valuation & Earnings

This table compares Claritev and its peers top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Claritev $965.41 million -$284.28 million -1.12
Claritev Competitors $342.79 million -$24.15 million 11.30

Claritev has higher revenue, but lower earnings than its peers. Claritev is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Claritev and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Claritev -27.05% N/A -5.74%
Claritev Competitors -749.77% -27.84% -15.02%

Institutional and Insider Ownership

87.2% of Claritev shares are held by institutional investors. Comparatively, 42.4% of shares of all “Healthcare Technology” companies are held by institutional investors. 7.4% of Claritev shares are held by company insiders. Comparatively, 16.2% of shares of all “Healthcare Technology” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Claritev beats its peers on 8 of the 13 factors compared.

About Claritev

(Get Free Report)

Claritev, formerly known as MultiPlan, provides technology-enabled services intended to help manage healthcare costs and support payment accuracy. Its offerings include access to provider networks, claims and payment solutions, and data analytics for evaluating healthcare costs and utilization. The company serves health plans, self-insured employers, third-party administrators and other participants in the U.S. healthcare system. Its services are designed to help customers identify cost-management opportunities and support more efficient healthcare transactions.

Receive News & Ratings for Claritev Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Claritev and related companies with MarketBeat.com's FREE daily email newsletter.